249 completed, 90 recruiting, 80 terminated, 57 active not recruiting. 575 Phase 2, 176 Phase 1, 27 Phase 3.
Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Rusfertide in Adults With Polycythemia Vera in China Rusfertide - Polycythemia Vera | Phase 2 | Not yet recruiting | Takeda | 24 | 2027-03-01 | 2026-08-28 |
| Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine - Hematological Malignancies | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 70 | 2027-02-28 | 2026-08-20 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Lanoracopan to Prevent Acute GVHD Following Haploidentical Peripheral Blood Stem Cell Transplantation: A Prospective Multicenter Single-Arm Exploratory Study Lanoracopan, Anti-thymocyte globulin (ATG), Calcineurin inhibitor (Cyclosporine or Tacrolimus) - Hematologic Malignancies, Haploidentical Peripheral Blood Stem Cell Transplantation | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 30 | 2026-12-01 | 2026-11-09 |
| Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers Cyclophosphamide, Busulfan, Fludarabine - Core Binding Factor Alpha Subunits, Hematologic Neoplasms | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 102 | 2026-11-18 | 2026-11-13 |
| High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy High-dose inactivated influenza vaccine, Standard-dose inactivated influenza vaccine - Hematologic Malignancy, Influenza | Phase 2 | Recruiting | Sung-Han Kim | 60 | 2026-11-02 | 2026-11-09 |
| Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera Epetraborole, Placebo - Polycythemia Vera (SNOMED CT: 109992005) | Phase 2 | Not yet recruiting | AN2 Therapeutics, Inc | 75 | 2026-11-01 | 2026-10-23 |
| CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus - Graft -Versus-host-disease | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 72 | 2026-11-01 | 2026-09-08 |
| A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera AG-236, Placebo - Polycythemia Vera | Phase 2 / Phase 3 | Not yet recruiting | Agios Pharmaceuticals, Inc. | 245 | 2026-11-01 | 2026-10-13 |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies MEN2312 - Hematological Malignancy | Phase 1 / Phase 2 | Not yet recruiting | Stemline Therapeutics, Inc. | 115 | 2026-10-30 | 2026-10-14 |
| A Study of Ropeg-Interferon in People With Polycythemia Vera Ropeginterferon - Polycythemia Vera (PV), JAK2 Mutation | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 55 | 2026-10-30 | 2026-11-03 |
| A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025). Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b - Polycythemia Vera | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 380 | 2026-10-29 | 2026-11-13 |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine) - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 60 | 2026-10-14 | 2026-11-13 |
| CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults CARCIK CD123/33 infusion - AML (Acute Myeloid Leukemia), BPDCN | Phase 1 / Phase 2 | Recruiting | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | 18 | 2026-10-01 | 2026-10-16 |
| A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms KK2430 - Hematologic Neoplasms | Phase 1 / Phase 2 | Recruiting | Kyowa Kirin Co., Ltd. | 72 | 2026-08-01 | 2026-08-07 |
| A Study of Rusfertide in Japanese Adults With Polycythemia Vera Rusfertide - Polycythemia Vera | Phase 2 | Recruiting | Takeda | 9 | 2026-07-14 | 2026-10-02 |
| A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Autologous nano CD5-CAR T Cells - T-Cell Acute Lymphoblastic Leukemia, T-Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2026-06-30 | 2026-07-01 |
| Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies Luspatercept, Epoetin - Luspatercept, Epoetin | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 90 | 2026-06-15 | 2026-06-09 |
| Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. Allogeneic TCR-enhanced Vδ2 T cell Injection, Cyclophosphamide injection, Fludarabine Injection - Hematologic Malignancy, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 24 | 2026-06-05 | 2026-06-08 |
Showing 20 of 575. Sign in to see all of them.
Polycythemia Vera (121) · Leukemia, Myeloid, Acute (117) · Multiple Myeloma (105) · Myelodysplastic Syndromes (99) · Primary Myelofibrosis (93) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (88) · Leukemia (87) · Lymphoma (85) · Myeloproliferative Disorders (80) · Lymphoma, Non-Hodgkin (76) · Thrombocythemia, Essential (74) · Leukemia, Lymphocytic, Chronic, B-Cell (63) · Hodgkin Disease (56) · Graft vs Host Disease (51)
Hemic and Lymphatic Diseases (574) · Neoplasms by Site (566) · Hematologic Diseases (555) · Neoplasms (530) · Neoplasms by Histologic Type (265) · Immune System Diseases (258) · Immunoproliferative Disorders (217) · Bone Marrow Diseases (215) · Lymphoproliferative Disorders (211) · Lymphatic Diseases (198) · Hemorrhagic Disorders (157) · Pathological Conditions, Signs and Symptoms (153) · Pathologic Processes (146) · Leukemia, Myeloid (132)
Cyclophosphamide (91) · fludarabine (63) · fludarabine phosphate (54) · Tacrolimus (53) · Mycophenolic Acid (52) · Whole-Body Irradiation (52) · Busulfan (47) · Methotrexate (31) · Melphalan (28) · Peripheral Blood Stem Cell Transplantation (27) · Antilymphocyte Serum (26) · Cyclosporine (22) · Stem Cell Transplantation (20) · Thiotepa (20) · thymoglobulin (19)
M.D. Anderson Cancer Center (52) · National Cancer Institute (NCI) (45) · Fred Hutchinson Cancer Center (26) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (13) · Novartis Pharmaceuticals (12) · Cancer Research UK (8) · Mayo Clinic (7) · Chinese PLA General Hospital (6) · H. Lee Moffitt Cancer Center and Research Institute (6) · Incyte Corporation (6) · Memorial Sloan Kettering Cancer Center (6) · University of Liege (6) · Bristol-Myers Squibb (5) · City of Hope Medical Center (5) · Dana-Farber Cancer Institute (5)
United States (384) · France (55) · Italy (54) · China (45) · United Kingdom (45) · Germany (40) · Spain (34) · Canada (33) · Australia (24) · Belgium (24) · Israel (20) · Netherlands (19) · Poland (16) · South Korea (14) · Denmark (9)
Neal Flomenberg, MD (7) · Alessandro Rambaldi, MD (6) · Matthew Krebs, Dr (6) · Christopher G Kanakry, M.D. (4) · Dolores Grosso, DNP, CRNP (4) · Jorge Cortes, MD (4) · Ruben A. Mesa, MD (4) · Usama Gergis, MD (4) · Yves Beguin, MD, PhD (4) · Andrew M Yeager, MD (3)
PMID 12171484, PMID 19282026, PMID 23065508, PMID 23524640, PMID 23802653, PMID 26408225, PMID 30904387, PMID 32160294, PMID 32416453, PMID 32463741, PMID 32499241, PMID 34515338, PMID 40313042, PMID 41485109, PMID 5449164, PMID 10204198, PMID 10515382, PMID 10573044, PMID 10845900, PMID 11013273, PMID 11301861, PMID 11468154, PMID 11719388, PMID 11939602, PMID 11985515, PMID 12659416, PMID 12663454, PMID 12692611, PMID 13411920, PMID 14113077, PMID 15064010, PMID 15110092, PMID 15528753, PMID 15602019, PMID 15845896, PMID 16115130, PMID 16192477, PMID 16616780, PMID 16709929, PMID 1671578, PMID 16732175, PMID 16980990, PMID 17162214, PMID 17507164, PMID 17606446, PMID 18307672, PMID 18451242, PMID 18468541, PMID 18489989, PMID 18500368
U10CA180820 (21), U24CA196172 (20), P30CA015704 (10), P01CA018029 (7), P30CA015083 (6), 2023 (5), P30CA016672 (5), 2017 (4), 2009 (3), 2025 (3), P01CA015396 (3), P01CA078902 (3), P01CA108671 (3), 2014 (2), 2016 (2)